• Citer

Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: A randomized phase 2b trial

par Andresen, Nikolai Kragøe;Røssevold, Andreas Hagen;Quaghebeur, Claire;Gilje, Bjørnar;Boge, Beate;Gombos, Andrea ;Falk, Ragnhild Sørum;Mathiesen, Randi Ruud;Julsrud, Lars;Garred, Oystein;Russnes, Hege Giercksky;Lereim, Ragnhild Reehorst;Chauhan, Sudhir Kumar;Lingjærde, Ole Christian;Dunn, Claire;Naume, Bjorn;Kyte, Jon Amund
Référence Journal for ImmunoTherapy of Cancer, 12, 1, e007990
Publication Publié, 2024-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: A randomized phase 2b trial
Auteur:	Andresen, Nikolai Kragøe; Røssevold, Andreas Hagen; Quaghebeur, Claire; Gilje, Bjørnar; Boge, Beate; Gombos, Andrea; Falk, Ragnhild Sørum; Mathiesen, Randi Ruud; Julsrud, Lars; Garred, Oystein; Russnes, Hege Giercksky; Lereim, Ragnhild Reehorst; Chauhan, Sudhir Kumar; Lingjærde, Ole Christian; Dunn, Claire; Naume, Bjorn; Kyte, Jon Amund
Informations sur la publication:	Journal for ImmunoTherapy of Cancer, 12, 1, e007990
Statut de publication:	Publié, 2024-01
Sujet CREF:	Généralités
Mots-clés:	Breast Neoplasms
	Immune Checkpoint Inhibitors
	Ipilimumab
	Nivolumab
	T-Lymphocytes, Regulatory
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2051-1426
	info:doi/10.1136/jitc-2023-007990
	info:scp/85182852784
	info:pmid/38242720